Market Research Blog

According to the FMI analyst, worldwide sales of general anesthesia drugs will increase ~3% year-over-year to total ~US$ 4.3 billion in 2019, up from US$ 4.17 billion in 2018. The analyst identifies growth opportunities in the development of new drugs that can overcome shortcomings such as adverse effects, procedural complications and allergic reactions.

As the development of ultra-short acting hypnotic or sedative agent without adverse effects remains an unfulfilled dream, a search for newer drugs and clinical trials of formerly withdrawn drugs to remove the undesirable effects while maintaining their beneficial effects have been underway. Collaborating with research institutes to understand the challenges in designing and developing effective drugs will continue to be a key focus area of manufacturers as well.

Propofol IV Drugs Continue to Witness Significant Adoption

Relatively high adoption of propofol intravenous drugs in large number of surgeries performed globally continues to influence growth strategies, which accounted for ~25% revenue share in 2018.

“While many anesthesiologists prefer the use of propofol for its lipophilic nature and rapid onset of action on the body, water soluble formulations of propofol are being developed to address the disadvantages associated with lipid formulations such as hyperlipidemia, pain on injection, and bacterial growth,” said the FMI analyst.

The FMI analyst predicts the sales of inhalation anesthetics such as sevoflurane to be valued at ~US$ 830 million in 2019, while the sales of desflurane is likely to increase 2.5% in that year. On the one hand, midazolam and remifentanil continue to represent the lowest revenue shares in the market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-388

Adoption in Ambulatory Surgical Centers to Ramp up in 2019

General anesthesia drugs worth US$ 1.8 billion were sold in hospitals in 2018, driven by rising number of hospitals along with the emergence of favorable reimbursement policies across the globe.

“A notable increase in ambulatory surgeries and rising utilization of general anesthesia drugs for outpatient procedures have been significantly contributing to the market growth,” said the FMI analyst.

In 2018, general anesthesia drugs sold in ambulatory surgical centers totaled a revenue worth ~US$ 1.4 billion, and is estimated to record 3% high in 2019.

North America, Europe, and East Asia Markets in the Vanguard

North America continues to acquire the leading position in general anesthesia drugs market, accounting for a 30% revenue share in 2018 total, followed by Europe and East Asia.

The FMI analyst anticipates a rising number of complexity of medical interventions requiring induction and maintenance of general anesthesia drugs in several nations in Europe, driven further by an ongoing aging of population. Sales in the region are likely to exhibit a CAGR of 3% during the forecast period.

East Asia (24% share) will continue to greater opportunities for the market players, in the view of rising approvals of drugs along with favorable government initiatives for the development of healthcare infrastructure.

“Although the demand for general anesthesia drugs directly correlates with the advancements in complex surgeries, manufacturers will need to direct their investments towards R&D for safer drugs, considering the uncertain study results relative to the impact of general anesthesia drugs on developing as well as aging brain,” said the FMI analyst.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-388

GENERAL ANESTHESIA DRUGS MARKET TAXONOMY

The global general anesthesia drugs market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

By Drug Class

• Propofol
• Sevoflurane
• Dexmedetomidine
• Desflurane
• Remifentanil
• Midazolam
• Others
• (Others – Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)

By Route of Administration

• Intravenous Anesthesia
• Inhaled Anesthesia

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/388

By Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• MEA

Major progress has been witnessed with 3D automatic CPR devices, especially when normal CPR device coupled with torso restraints providing vertical compression and high quality resuscitation.

Automated CPR devices experienced a surge in demand during the Covid-19 pandemic. COVID-19 infected heart patients were more susceptible to cardiac arrest in comparison with non infected patients. With rapid mutation of virus, the patients were facing higher risk of cardiac arrest.

The market is anticipated to grow significantly over the forthcoming decade, as majority of coronary and intensive care units are inclining towards automated CPR devices for its high effectiveness.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-720

Key Takeaways from FMI’s Automated CPR Devices Market Study

• Presence of modern healthcare infrastructure and high per capita income will bolster demand across the U.S.
• The U.K is expected to offer growth opportunities as governments and private organizations are working towards spreading awareness regarding dangers of cardiovascular diseases.
• Rising prevalence of obesity and high blood pressure which are precursor to cardiac arrest will increase automated CPR devices adoption across France.
• China will offer lucrative opportunities owing to increasing alcohol and tobacco consumption and developing healthcare infrastructure.
• India is expected to exhibit impressive market growth owing to increase in geriatric population and growing incidence of sudden cardiac arrest in the country.

 “Rising consumer awareness regarding benefits of CPR devices and increasing adoption in EMT services will amplify sales of automated CPR devices during the forecast period,” says the FMI analyst.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-720

Competitive Landscape

Automated CPR market is highly consolidated owing to presence of regional and global market players. Key market players in automated CPR devices market are focusing towards employing inorganic market strategies to expand their global foothold.

Inorganic strategies include strategic merger and acquisition and forming an alliance with regional distributors to strengthen their supply chain channels.

They are also emphasizing towards faster product approvals, product development and patenting. New market entrants are focusing on new product launches to establish their market presence.

For instance, Michigan Instruments launched hand-free automatic CPR device which is light weight, portable and helps in smooth transition from manual CPR to automated compressions.

ZOLL Medical Corporation introduced a new automated CPR devices system “Autopulse” which assists EMS personnel in providing high quality chest compressions in cramped spaces and steep down stairwells.

Prominent players operating in the automated CPR devices market are SunLife Science Inc., ZOLL Medical Corporation, Michigan Instruments, Physio Control Inc., Brunswick Biomedical Technologies, Zhuhai Kindway Medical Science & Technology Co. Ltd, CPR Medical Devices Inc., and Medtronic Inc.

Continuous glucose monitoring systems are adopted by many end-users including household, and hospitals and diagnostics centers. There is an increase in the usage of continuous glucose monitoring systems components in hospitals and diagnostic centers due to an increase in the demand for sensor.

Currently, companies are focusing on continuous development and the introduction of innovative continuous glucose monitoring system devices to receive FDA approval for various brands, which has led to high competitiveness in the market. Scientists are conducting research and testing continuous glucose monitoring systems to provide effective systems and aid better management of diabetes.  Thus, there is scope for the introduction of new and advanced continuous glucose monitoring systems in the near future. Market players operating in the continuous glucose monitoring systems market are focused towards the integration of advanced technologies in products in order to offer variations and trends in the type of blood glucose level display.

On the other hand, the high cost of continuous glucose monitoring systems acts as a restrain for the growth of the market as treatment with continuous glucose monitoring systems costs around US$ 4,930 to US$ 7,120 per person. This makes it unaffordable for a large portion of the global population. For instance, glucose monitors used in continuous glucose monitoring systems cost between US$ 1,000 and US$ 1,400, while sensors cost between US$ 35 and US$ 100 apiece. Besides this, sensors have a very short lifespan – around 3 to 7 days – since they are prone to biofouling, which affects the accuracy of the continuous glucose monitoring systems.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-694

Due to the lack of accuracy in the readings of glucose levels in critical cases, continuous glucose monitors are incapable of preventing severe hypoglycemia stage, in which the glucose level in the body is extremely low. For instance, continuous glucose monitoring systems are up to 21% less accurate when compared with actual plasma glucose values and this percentage increases when there is a rapid rise and fall in plasma glucose. According to the results of studies, it is estimated that the probable reason behind this problem is the real-time performance delay of continuous glucose monitoring systems.

The global continuous glucose monitoring systems market has been categorized on the basis of component into transmitter & monitor, sensor and insulin pump. On the basis of end-use, the continuous glucose monitoring systems market has segmented into household and hospitals and diagnostics centers. In terms of revenue, the household segment dominated the global continuous glucose monitoring systems market. Hospital and diagnostics centers segments are anticipated to expand at the fastest CAGRs over the forecast period.

This continuous glucose monitoring systems report also covers trends that drive each segment and offers analysis & insights regarding the potential of the continuous glucose monitoring systems market in regions such as North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East & Africa, and Japan. Among these regions, the APEJ continuous glucose monitoring systems market is projected to exhibit relatively high growth in the global continuous glucose monitoring systems market with a CAGR of 16% over the forecast period. Revenue from the continuous glucose monitoring systems market in APEJ accounted for over 7% of the global continuous glucose monitoring systems market revenue in 2015. Providers of continuous glucose monitoring systems can focus on expanding across several countries in APEJ such as India and China.

Some of the key competitors in the continuous glucose monitoring systems market include Abbott, Medtronic, Dexcom, Animas, Roche, Bayer, Glysens and Ypsomed. These key players are constantly focusing on product innovation and geographical expansion to sustain their market presence and increase revenue generation by developing various types of devices and delivering outstanding offerings to several end-users.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-694

Key Segments Covered in the continuous glucose monitoring system MarketComponent

• Transmitter & monitor
• Sensor
• Insulin Pump

End-user

• Household, and hospitals
• Diagnostics Centres

Key Regions Covered

• North America
• Latin America
• Western Europe
• Eastern Europe
• Japan
• APEJ
• Middle East & Africa

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-694

The report is focused on basic first aid products such as adhesive bandages, disinfectants and gauzes. Though the basic wound care segment in China accounts for miniscule share of the overall wound care market in China, it is expected to witness significant growth over the next few years. Increasing awareness about non-traditional first-aid products among consumers in Tier 2 and Tier 3 cities is the prime driving factor for the market in the region.

As of 2014, basic first aid products accounted for less than 20% share of the overall wound care market in China. Strategies such as innovative product packaging along with aggressive market campaigning has led to surge in demand for these products in China. Government emphasis on healthcare policies, liberalization of policies related to distribution of licenses and FDI influx are other key driving factors of the first aid market in China. On the flipside, low healthcare expenditure and higher preference for Chinese traditional medicines among consumers is a major restraint for non-traditional wound care product manufacturers.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-cn-659

The report analyses the China first aid market in terms of sales revenue (US$ Mn) by product, cities and by retail sales channel and provides information regarding market dynamics, value chain, competitive landscape, current trends, market estimations and forecast.

On the basis of city, the China first-aid market has been segmented into Tier 1, Tier 2 and Tier 3 Cities. Among Tier 1 cities, Shanghai offers good market opportunities for first-aid products manufacturers. It is anticipated to generate 1.4X higher sales revenue by the end of the forecast period as compared to that in 2014. Disinfectant products are anticipated to account for over half of the sales revenue in Tier 1 cities, followed by gauzes and bandages respectively. Tier 2 cities are expected to generate 1.3X higher revenue than Tier 3 cities by the end of 2020.

Among retail sales channels, drugstores and pharmacies are key channels for sales of adhesive bandages. Hospitals are the key channel for sales of gauzes. Hospitals account for major share of retail sales in Tier 3 cities in China. Though drugstores, pharmacies and hospitals are key retail sales channels for adhesive bandages and gauzes, modern retail sales channel are the most preferred mode for sales of disinfectants. Hypermarkets and supermarkets account for over 60% share of retail sales of disinfectants.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-cn-659

By product type, the China first aid market has been segmented into adhesive bandages, gauzes and disinfectants (antiseptics). While disinfectants are projected to be the largest market segment throughout the forecast period, its presence is limited to Tier 1 and Tier 2 cities in China. The disinfectant products segment is anticipated to register a CAGR of 7.5% between 2014 and 2020. Reckitt Benckiser and Walch are key players in this product segment. Organized players account for significant market share in the disinfectants products segment. Among products, gauzes (woven and non-woven) covers significant market in Tier 3 cities in China. Sales revenue of adhesive bandages is further segmented into butterfly stiches, transdermal bandages and special bandages. Transdermal bandages account for significant market share in the adhesive bandages segment.

Key players in the China first aid market include Johnson and Johnson, Winner Medical Group Co., Reckitt Benckiser, Yunnan Baiyao, 3M Company, Nepstar Drugstore, 7-Eleven, Beijing Hualian Group and A.S Watson Group.

Key SegmentBy Product Type

• Bandages
• Gauzes
• Disinfectants

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-cn-659

High content screening is adopted for drug discovery and development. Increasing research in search of the novel drug candidate and target identification & validation is expected to propel the adoption of high content screening over the forecast years. Besides this, continuous focus on manufacturing high quality and technologically advanced cell imaging system is expected to accelerate demand over the course of the forecast period.

However, due to COVID 19 outbreak, the research and development activities were hampered immensely. This is expected to have a negative impact on the market. Nonetheless, increasing investments by key manufacturers in the development of advanced cell imaging product is expected to boost the market in the coming years.

Key Takeaways of High Content Screening Market Study

• The high content screening market will rise at register a little below 5% y-o-y growth in 2021, following a brief period of restrictions amid COVID-19
• Presence of a sophisticated healthcare and pharmaceutical infrastructure is enabling the U.S. market account for over 90% of sales in North America
• The U.K. will register an impressive 7.2% y-o-y growth in 2021 driven by increasing focus on research and development activities in the pharmaceutical sector
• Demand registered in Germany and France is expected to rise significantly within Europe
• Favorable government policies will support expansion in Japan, followed by China

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-426

“Demand for novel technologies for cell analysis and drug discovery is expected to improve the manufacturing speed, throughput, and reliability. This is expected to create growth opportunities for market players,” Says the FMI Analyst.

Who is Winning?The key manufacturers in the high content screening market are involved in several partnerships and collaboration to develop new cell imaging technology. The leading manufacturers are also making their business strategies by making collaborations with international laboratories and research institutes to develop new imaging technologies.

For instance, In December 2019, Leica Microsystems make a collaboration agreement with the European Molecular Biology Laboratory (EMBL) to develop new imaging technologies applicable in life science. With this agreement EMBL and Leica promoting new imaging technologies for cell imaging.

Valuable Insights into High Content Screening Market StudyFuture Market Insights offers actionable insights and a unique perspective on the high content screening market in its latest study, presenting historical demand assessment from 2016 – 2020 and projections from 2021–2031 based on product (cell imaging & analysis, consumables, Softwares, services), industry (pharmaceutical & healthcare, biotechnology, educational institutions, independent CRO, government organizations and others), and by application (primary & secondary screening, target identification & validation, toxicity studies, compound profiling and others) in seven key regions.